HC Wainwright Downgrades NeuroSense Therapeutics to Neutral
HC Wainwright cut its rating on NeuroSense Therapeutics from Buy to Neutral. Shares were reported at 1.15.
Related stories
Papaya Owes $730 Million Judgment to Skillz Platform
M impact | EQUITY | Nov 02, 2026, 07:25 PM UTC
Tutor Perini unit wins $60 million Coast Guard contract
Tutor Perini said its subsidiary, Perini Man, received a $60 million US Coast Guard contract.
M impact | EQUITY | Nov 02, 2026, 07:22 PM UTC
US Equity Indexes Rise as Crude Oil and Treasury Yields Fall
M impact | EQUITY | Nov 02, 2026, 07:22 PM UTC
Meta plans potential bond sale to raise at least 200 hundred million dollars
Meta is planning a potential cross-border bond issue to raise at least 200 hundred million dollars, according to Bloomberg, Reuters reports.
M impact | EQUITY | Nov 02, 2026, 07:19 PM UTC
Lumentum shares fall more than 17%
Lumentum shares are down more than 17%, with Marvell weakness eroding the value of the all-stock takeover.
M impact | EQUITY | Nov 02, 2026, 07:19 PM UTC
報道：メタ、債券発行で少なくとも200億ドル調達を目指す
M impact | EQUITY | Nov 02, 2026, 07:19 PM UTC